Insider Selling: AbbVie (NYSE:ABBV) EVP Sells $5,147,630.00 in Stock

AbbVie Inc. (NYSE:ABBV) EVP Perry Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

AbbVie Stock Up 3.1%

Shares of NYSE:ABBV opened at $231.69 on Monday. The stock has a market cap of $409.66 billion, a PE ratio of 98.17, a PEG ratio of 0.81 and a beta of 0.35. The company’s fifty day moving average is $224.34 and its 200 day moving average is $223.26. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is presently 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital Markets initiated coverage with an Outperform rating and a $260 price target, arguing AbbVie’s growth is durable and the shares have been punished by short‑term competitive concerns — a bullish analyst catalyst that likely supported buying interest. RBC Launches AbbVie Coverage
• Positive Sentiment: The U.S. Justice Department publicly backed AbbVie’s challenge to Colorado’s 340B guidance, giving the company federal support in a case that could affect how discounts are applied and future margin outcomes in that program. DOJ backs AbbVie in 340B fight
• Positive Sentiment: Federal agencies also supported AbbVie’s position in Colorado in separate coverage, reinforcing regulatory/legal momentum in the company’s favor that could protect 340B economics if courts rule similarly. Feds back AbbVie in Colorado 340B fight
• Positive Sentiment: AbbVie received FDA approval for a first‑in‑class, all‑oral fixed‑duration regimen for untreated CLL and announced a $380M U.S. manufacturing buildout to support neuroscience and obesity programs — both add to medium‑term revenue and capacity upside. AbbVie’s CLL Breakthrough And US$380m Build Out
• Positive Sentiment: AbbVie reported fresh real‑world/post‑marketing data updates for upadacitinib (Rinvoq) in teens with eczema — data investors should watch for uptake and label/market expansion implications for a key growth franchise. Upadacitinib Study in Teens
• Neutral Sentiment: Zacks highlights AbbVie as a top long‑term value stock based on style scores — a framing piece that supports a buy thesis but doesn’t present new company‑specific catalysts. Why AbbVie is a Top Value Stock
• Neutral Sentiment: Dividend and longer‑term outlook pieces (Seeking Alpha / Motley Fool) reiterate AbbVie’s income profile and buy‑and‑hold case, helpful context for income investors but unlikely to trigger near‑term moves alone. Health Care Q4 Dividend Roundup
• Negative Sentiment: A Tennessee court rejected AbbVie’s challenge to that state’s contract‑pharmacy law, a loss that keeps legal/regulatory uncertainty around 340B implementation and potential margin headwinds in some states. AbbVie Loses Challenge in Tennessee

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC grew its position in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. increased its stake in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares in the last quarter. Buck Wealth Strategies LLC lifted its holdings in shares of AbbVie by 49.2% during the second quarter. Buck Wealth Strategies LLC now owns 2,209 shares of the company’s stock valued at $410,000 after purchasing an additional 728 shares during the last quarter. Finally, HBK Sorce Advisory LLC boosted its position in shares of AbbVie by 2.3% in the 2nd quarter. HBK Sorce Advisory LLC now owns 20,995 shares of the company’s stock worth $3,897,000 after purchasing an additional 473 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ABBV shares. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a report on Tuesday, January 20th. JPMorgan Chase & Co. raised their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.